How does this data stack up to Benlysta? There's reference to the data being stat sig, although no specific p-values are given. IMMU only has about a $250M market cap it appears (not sure about fully-diluted numbers) so if epratuzumab has the potential to be better than Benlysta, presumably IMMU may be worth a look.
Separately, any other small-cap biotechs targeting CD22?
News 
Market Data 
Discover 
